Veronique Danel
Lille, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Tofersen Treatment in SOD1-ALS: Real-World Evidence from a Retrospective Multicenter Study in France (FORSLA Study).
Journal: Mayo Clinic proceedings. Innovations, quality & outcomes
Published: August 04, 2026
Primary Lateral Sclerosis French National Diagnostic and Care Protocol.
Journal: Revue neurologique
Published: April 01, 2026
Prevalence of SOD1 and C9orf72 Variants Among French ALS Population: The GENIALS Study.
Journal: European journal of neurology
Published: May 01, 2025
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: October 25, 2024
Assessing the upper motor neuron in amyotrophic lateral sclerosis using the triple stimulation technique: A multicenter prospective study.
Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
Published: April 21, 2021
Effect of familial clustering in the genetic screening of 235 French ALS families.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: September 06, 2020
Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort.
Journal: Frontiers in neuroscience
Published: February 12, 2020
Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Journal: Journal of neural transmission (Vienna, Austria : 1996)
Published: November 21, 2019
Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis.
Journal: Annals of clinical and translational neurology
Published: September 20, 2019
Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
Journal: Antioxidants & redox signaling
Published: December 31, 2017
A novel mutation of the C-terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: January 06, 2017
Showing 1-11 of 11
Last Updated: 09/26/2026